Memantine as Adjunctive Therapy in Children Diagnosed With Autistic Spectrum Disorders: An Observation of Initial Clinical Response and Maintenance Tolerability

  title={Memantine as Adjunctive Therapy in Children Diagnosed With Autistic Spectrum Disorders: An Observation of Initial Clinical Response and Maintenance Tolerability},
  author={Michael G. Chez and Quinn Burton and Timothy Dowling and Min-Te Chang and Pavan Khanna and C. Kramer},
  journal={Journal of Child Neurology},
  pages={574 - 579}
Autism and Pervasive Developmental Disorder Not Otherwise Specified are common developmental problems often seen by child neurologists. There are currently no cures for these lifelong and socially impairing conditions that affect core domains of human behavior such as language, social interaction, and social awareness. The etiology may be multifactorial and may include autoimmune, genetic, neuroanatomic, and possibly excessive glutaminergic mechanisms. Because memantine is a moderate affinity… 

Use of Memantine in Autism Spectrum Disorder: a Case Report

Memantine appeared effective for treating core deficits in verbal and sign language in an 11-year-old Caucasian male with autism, following parental request after learning of a phase II clinical trial utilizing the drug for treatment in autism.

Pharmacologic Treatment of Behavioral Symptoms Associated With Autism and Other Pervasive Developmental Disorders

Serotonin reuptake inhibitors are of limited efficacy in children and adolescents, but risperidone and aripiprazole have been shown to reduce these symptoms, and there remains a need for further safety and efficacy research in this area.

Drug therapy in autism: a present and future perspective.

Pharmacotherapy to control behavioral symptoms in children with autism

Psychotropic medications examined in this review include serotonin reuptake inhibitors, typical and atypical antipsychotics, medications used to treat attention-deficit/hyperactivity disorder, naltrexone, buspirone, divalproex sodium, lamotrigine, levetiracetam, memantine, mirtazapine, riluzole, pioglitazone, and topiramate.

Memantine for autism spectrum disorder.

There was no clear evidence of a difference between memantine and placebo with respect to severity of core symptoms of autism, although the evidence is very uncertain about the evidence.

Psychopharmacological Interventions in Autism Spectrum Disorder

The physician should be better able to prescribe the appropriate psychotropic medication to treat symptoms of ASD and identify the side effects of the psychotropic medications used to treat ASD.

Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) – study protocol for a randomised controlled trial

This proof-of-concept clinical study will allow pilot-testing of memantine for both clinical effectiveness and tolerability/safety and will provide clinically relevant solid information on potential new mechanisms and medication treatment in obsessive-compulsive and autism spectrum disorders.

Current Enlightenment About Etiology and Pharmacological Treatment of Autism Spectrum Disorder

The diversity of numerous aetiological factors and the alterations in variety of neurotransmitter generation, release and function linked to ASD are discussed with focus on drugs currently used to manage neuropsychiatric symptoms related to ASD.



Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate.

Improvements in both expressive speech and overall autistic behavior showed gains were statistically significant and supported the hypothesis that treatment with cholinergic enhancing drugs in autistic spectrum disorders yields positive therapeutic effects.

Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder.

  • B. KingD. M. Wright E. Cook
  • Medicine, Psychology
    Journal of the American Academy of Child and Adolescent Psychiatry
  • 2001
Improvements in behavioral ratings following treatment with amantadine suggest that further studies with this or other drugs acting on the glutamatergic system are warranted, and the design of these drug trials in children with autistic disorder must take into account the possibility of a large placebo response.

Neuroglial activation and neuroinflammation in the brain of patients with autism

It is indicated that innate neuroimmune reactions play a pathogenic role in an undefined proportion of autistic patients, suggesting that future therapies might involve modifying neuroglial responses in the brain.

Mental health in the United States: parental report of diagnosed autism in children aged 4-17 years--United States, 2003-2004.

Estimates suggest that, as of 2003-2004, autism had been diagnosed in at least 300,000 U.S. children aged 4-17 years and were associated with reported social, emotional, and behavioral symptoms and specialized needs.

Outcome Measures for Clinical Drug Trials in Autism

This paper identifies instruments and measures that may be appropriate for randomized clinical trials in participants with autism spectrum disorders (ASDs), and recommends routine elicitation of side effects, height and weight, vital signs, and extrapyramidal side-effects assessment.

The Neurobiology of Autism

Thoroughly updated, The Neurobiology of Autism remains the best single-volume work on the wide array of research being conducted into the causes, characteristics, and treatment of autism.

Histoanatomic observations of the brain in early infantile autism

Abnormalities were found in the hippocampus, subiculum, entorhinal cortex, septal nuclei, mamillary body, selected nuclei of the amygdala, neocerebellar cortex, roof nuclea of the cerebellum, and inferior olivary nucleus.

Postmortem brain abnormalities of the glutamate neurotransmitter system in autism

Subjects with autism may have specific abnormalities in the AMPA-type glutamate receptors and glutamate transporters in the cerebellum, which may be directly involved in the pathogenesis of the disorder.